세계의 중추신경계 치료 시장 : 질환별, 약제 유형별, 투여 경로별, 최종사용자별 - 예측(2025-2030년)

The Central Nervous System Therapeutics Market was valued at USD 133.83 billion in 2023 and is projected to grow to USD 143.11 billion in 2024, with a CAGR of 7.24%, reaching USD 218.45 billion by 2030.

The field of central nervous system therapeutics is rapidly evolving and redefining its approach to treatment, diagnosis, and patient management. Over recent years, advances in research, technology, and clinical methodologies have collectively paved the way for a more personalized and innovative practice in treating complex neurological disorders. Substantial research investments and a heightened understanding of disease mechanisms are driving the development of more targeted therapies that address long-standing challenges in healthcare.

The landscape is marked by emerging translational research and an integration of sophisticated diagnostic tools that enable clinicians and researchers to identify early biomarkers and predict disease trajectories with increasing accuracy. This era of transformation is not merely about incremental refinement; it represents a paradigm shift in how central nervous system disorders are managed, with an emphasis on precision medicine.

Progress in preclinical and clinical studies has accelerated the identification and validation of new molecular targets. As a result, stakeholders are now equipped with enhanced tools to evaluate efficacy and safety across diverse patient populations, ensuring that therapeutic solutions are not only effective but also well tailored to individual needs. This introduction sets the stage for understanding the multifaceted developments that are transforming CNS therapeutics worldwide.

Transformative Shifts Reshaping the CNS Therapeutics Landscape

Recent years have witnessed a wave of transformative shifts across the central nervous system therapeutics landscape, driven by groundbreaking innovations in drug development, regulatory reforms, and strategic market dynamics. The integration of advanced data analytics and genomics has accelerated the identification of novel therapeutic targets, enabling more nuanced approaches to treatment that were once considered the realm of possibility only in the future.

Stakeholders in this sector have experienced a significant transformation as the boundaries between clinical research and real-world evidence blur. This synergy has fostered a collaborative environment wherein academic institutions, biotechnology firms, and pharmaceutical companies work jointly to quicken the pace from discovery to patient delivery. Such partnerships are not only reducing the time-to-market for promising innovations but are also infusing the industry with fresh perspectives on tackling neurological disorders.

In parallel, digital transformation has spurred the adoption of artificial intelligence and machine learning techniques for drug discovery and patient monitoring. This evolution supports more accurate predictive modeling, enhances clinical trial designs, and optimizes patient stratification, ultimately leading to more effective and safer treatments. Regulatory agencies globally are also evolving, providing accelerated pathways and flexible frameworks to ensure that new therapies, once proved safe and efficacious, can be rapidly integrated into clinical practice.

Moreover, the rise in personalized medicine underscores a burgeoning shift from the traditional one-size-fits-all approach toward more patient-specific interventions. These transformative trends are reshaping market dynamics and reorienting strategies, establishing a robust foundation for the next generation of CNS therapeutics.

Key Segmentation Insights Shaping Market Strategies

A detailed examination of market segmentation unveils critical insights that steer strategic decision-making in the domain of CNS therapeutics. A primary segmentation assessment based on disorders provides a comprehensive view of the market where different neurological conditions are stratified into distinct categories. The market is analyzed based on epileptic disorders, neurodegenerative diseases, pain management, and psychiatric disorders. Within epileptic disorders, the focus is further refined to delineate between epilepsy and seizure disorders. In the area of neurodegenerative diseases, attention is given to Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease. Similarly, pain management is dissected into acute pain, chronic pain, and neuropathic pain while psychiatric disorders encompass anxiety disorders, bipolar disorder, depression, and schizophrenia.

Further segmentation based on drug type divides market analysis into biologics and small molecules. Within the realm of biologics, the investigation extends to gene therapies, monoclonal antibodies, peptides, and stem cell therapies, revealing opportunities and challenges that are unique to each subcategory. Route of administration forms another crucial segmentation dimension where products are categorized as injectable, oral, and transdermal. In the injectable category, evaluation extends to intramuscular, intravenous, and subcutaneous methods, ensuring that delivery mechanisms are optimized for maximum patient compliance and therapeutic effect.

Finally, understanding the market through the lens of end-users-hospitals, research institutes, and specialty clinics-offers valuable perspectives on potential adoption rates and therapeutic impact. This multiplicity of segmentation factors provides a holistic overview, enabling industry stakeholders to tailor their approaches, mitigate risks, and capitalize on emerging opportunities in a highly competitive landscape.

Based on Disorders, market is studied across Epileptic Disorders, Neurodegenerative Diseases, Pain Management, and Psychiatric Disorders. The Epileptic Disorders is further studied across Epilepsy and Seizure Disorders. The Neurodegenerative Diseases is further studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease. The Pain Management is further studied across Acute Pain, Chronic Pain, and Neuropathic Pain. The Psychiatric Disorders is further studied across Anxiety Disorders, Bipolar Disorder, Depression, and Schizophrenia.

Based on Drug Type, market is studied across Biologics and Small Molecules. The Biologics is further studied across Gene Therapies, Monoclonal Antibodies, Peptides, and Stem Cell Therapies.

Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.

Based on End-Users, market is studied across Hospitals, Research Institutes, and Specialty Clinics.

Key Regional Trends and Market Opportunities

Geographical variations play an essential role in shaping the landscape of CNS therapeutics. Trends observed across various regions indicate a divergence in market dynamics and investment philosophies. In the Americas, substantial emphasis is placed on advancing innovative treatments and bolstering the integration of digital health technologies within clinical settings. Regulatory environments in this region tend to favor rapid adoption of breakthrough therapies, creating fertile ground for accelerated clinical trials and strategic public-private partnerships.

In regions spanning Europe, the Middle East, and Africa, robust healthcare infrastructures and the availability of skilled professionals have led to the establishment of centers of excellence. These regions focus on adopting evidence-based practices and optimizing patient care protocols. Strategic investments in research facilities, along with supportive government initiatives, contribute to a steady expansion of tailored therapeutic solutions in these diverse territories.

The Asia-Pacific region represents a dynamic and rapidly evolving market where increasing healthcare expenditures and a growing emphasis on life sciences are driving significant research and development activities. A surge in clinical trials aligned with disease prevalence, coupled with an expanding patient base, positions this region as a critical player in the global CNS therapeutics market. Together, these regional insights present a mosaic of opportunities and challenges that necessitate a nuanced strategy, tailored to the regulatory, economic, and socio-cultural specificities of each market.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Influential Market Players and Competitive Dynamics

An in-depth analysis of key companies within the CNS therapeutics arena reveals an intensely competitive landscape marked by continual innovation and strategic expansion. Industry giants such as AbbVie Inc., AC Immune SA, and Acadia Pharmaceuticals Inc. have established themselves as pioneers through their relentless focus on research and development. These companies, in collaboration with firms like Acorda Therapeutics, Inc. and Alkermes PLC, have spearheaded numerous clinical trials that underscore a commitment to advancing therapeutic frontiers.

Major players including Amgen Inc., AstraZeneca PLC, Bayer AG, and Biogen Inc. continue to diversify their portfolios by investing in both biologics and small molecule therapies. The competitive environment is further enriched by the contributions of Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, and Cassava Sciences, Inc., which have leveraged emerging technologies to streamline drug discovery and clinical validation processes. Companies such as Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., and Eisai Co. Ltd. remain at the cutting edge by integrating digital tools into their product development strategies, ensuring that delivery methods and therapeutic outcomes are consistently optimized.

Other influential entities, including Eli Lilly and Company, F. Hoffmann-La Roche AG, and GlaxoSmithKline PLC, have embraced partnerships and collaborative ventures to bridge gaps between research and clinical practice. H. Lundbeck A/S, Intra-Cellular Therapies, Inc., and Ipsen S.A. have driven innovation through targeted investments in precision medicine, while stalwarts such as Johnson & Johnson Services, Inc., Lupin Limited, and MapLight Therapeutics, Inc. foster a culture of continuous improvement. The landscape is further defined by contributions from Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., and Polpharma Biologics S.A. with final strategic inputs from Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A. These companies collectively shape competitive dynamics and drive forward the evolution of CNS therapeutics on a global scale.

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Alkermes PLC, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cassava Sciences, Inc., Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intra-Cellular Therapies, Inc., Ipsen S.A., Johnson & Johnson Services, Inc., Lupin Limited, MapLight Therapeutics, Inc., Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., Polpharma Biologics S.A., Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A.. Actionable Recommendations for Industry Leaders

Industry leaders are presented with a unique opportunity to capitalize on the rapid advancements within CNS therapeutics through strategic investments and collaborative innovation. It is imperative for decision-makers to enhance R&D pipelines by focusing on evidence-based outcomes and leveraging cutting-edge technologies. Prioritizing precision medicine initiatives and investing in biomarker research can yield substantial benefits by enabling early diagnosis and tailored treatment plans.

Furthermore, fostering partnerships between academia, biotechnology firms, and healthcare providers is key to navigating the complexities of central nervous system disorders. Collaborative research can lead to the shared development of robust clinical data, reducing the uncertainty that accompanies novel therapeutic discoveries. Emphasis should also be placed on diversifying clinical trial portfolios to encompass a broad spectrum of patient demographics and regional considerations, thereby ensuring that therapies are adaptable to varying market needs.

Leaders should explore opportunities to integrate digital health solutions, including artificial intelligence and machine learning, to enhance patient monitoring and streamline regulatory submissions. By adopting these actionable recommendations, industry players can mitigate risk, improve market responsiveness, and accelerate the delivery of innovative CNS therapies to the global patient community.

Conclusion: A Vision for the Future of CNS Therapeutics

In summary, the current phase in central nervous system therapeutics is defined by transformative innovations and collaborative endeavors that promise to reshape treatment paradigms. Through an integrated approach combining cutting-edge research, dynamic segmentation analysis, and regional market insights, stakeholders are well positioned to navigate an increasingly complex therapeutic landscape.

The synthesis of progressive drug development strategies and digital advancements underscores a commitment to precision medicine that is increasingly tailored to the individual needs of patients worldwide. As industry leaders continue to invest in innovative solutions and forge strategic alliances, the future of CNS therapeutics appears poised for substantive breakthroughs. This conclusion encapsulates the vital insights and emerging opportunities that serve as a roadmap for sustained growth and excellence in the field.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing elderly population and the prevalence of neurodegenerative disorders
    • 5.1.1.2. Implementation of government initiatives & funding for research on neurological disorders
  • 5.1.2. Restraints
    • 5.1.2.1. Rising cases of product recall associated with the CNS drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
    • 5.1.3.2. Potential utilization of nanomaterials for innovative drug formulation
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disorders: Increasing epileptic disorder prevalence and significant unmet medical needs
  • 5.2.2. Drug Type: Innovative biologics for particular and potent treatments
  • 5.2.3. Route of Administration: High preference for injectable routes owing to their long-acting formulations
  • 5.2.4. End-Users: Significant demand for CNS therapeutics in hospitals for immediate interventions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Central Nervous System Therapeutics Market, by Disorders

• 6.1. Introduction
• 6.2. Epileptic Disorders
  • 6.2.1. Epilepsy
  • 6.2.2. Seizure Disorders
• 6.3. Neurodegenerative Diseases
  • 6.3.1. Alzheimer's Disease
  • 6.3.2. Amyotrophic Lateral Sclerosis
  • 6.3.3. Multiple Sclerosis
  • 6.3.4. Parkinson's Disease
• 6.4. Pain Management
  • 6.4.1. Acute Pain
  • 6.4.2. Chronic Pain
  • 6.4.3. Neuropathic Pain
• 6.5. Psychiatric Disorders
  • 6.5.1. Anxiety Disorders
  • 6.5.2. Bipolar Disorder
  • 6.5.3. Depression
  • 6.5.4. Schizophrenia

7. Central Nervous System Therapeutics Market, by Drug Type

• 7.1. Introduction
• 7.2. Biologics
  • 7.2.1. Gene Therapies
  • 7.2.2. Monoclonal Antibodies
  • 7.2.3. Peptides
  • 7.2.4. Stem Cell Therapies
• 7.3. Small Molecules

8. Central Nervous System Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
  • 8.2.1. Intramuscular
  • 8.2.2. Intravenous
  • 8.2.3. Subcutaneous
• 8.3. Oral
• 8.4. Transdermal

9. Central Nervous System Therapeutics Market, by End-Users

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Research Institutes
• 9.4. Specialty Clinics

10. Americas Central Nervous System Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Central Nervous System Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Amneal Pharmaceuticals receives FDA approval for CREXONT to enhance Parkinson's therapy
  • 13.3.2. Asceneuron secures USD 100M to advance ASN51 for neurodegenerative diseases
  • 13.3.3. Eli Lilly's Kisunla receives FDA approval for early Alzheimer's treatment
  • 13.3.4. Roche and Ascidian Therapeutics join forces to develop innovative RNA therapies for neurological diseases
  • 13.3.5. Voyager Therapeutics initiates Phase 1a trial of VY-TAU01 for Alzheimer's
  • 13.3.6. Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830
  • 13.3.7. Sanofi India partners with Cipla to enhance distribution and promotion of CNS therapeutics to improve patient outcomes
  • 13.3.8. Engrail Therapeutics secures USD 157M Series B funding to advance non-addictive CNS therapies and expand strategic partnerships
  • 13.3.9. Myrobalan Therapeutics secures USD 24 million in Series A funding to advance CNS treatments
  • 13.3.10. AbbVie launches Produodopa, a groundbreaking 24-hour subcutaneous infusion therapy for advanced Parkinson's in the EU
  • 13.3.11. 4D Molecular Therapeutics and Arbor Biotechnologies partner to advance innovative genetic therapies for CNS disorders
  • 13.3.12. MapLight Therapeutics secures USD 225 million Series C funding to advance CNS therapies
  • 13.3.13. Pharmanovia expands neurology portfolio by acquiring 11 CNS brands from Sanofi
  • 13.3.14. Novartis strengthens neuroscience pipeline with USD 500M acquisition of siRNA-focused DTx Pharma
  • 13.3.15. Neurocrine Biosciences collaborates with Voyager Therapeutics on USD 175M gene therapy deal
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. F. Hoffmann-La Roche AG
  • 13.4.2. Bristol-Myers Squibb Company
  • 13.4.3. Lupin Limited
  • 13.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. AC Immune SA
• 3. Acadia Pharmaceuticals Inc.
• 4. Acorda Therapeutics, Inc.
• 5. Alkermes PLC
• 6. Amgen Inc.
• 7. AstraZeneca PLC
• 8. Bayer AG
• 9. Biogen Inc.
• 10. Bristol-Myers Squibb Company
• 11. C.H. Boehringer Sohn AG & Co. KG
• 12. Cassava Sciences, Inc.
• 13. Cipla Limited
• 14. CNS Pharmaceuticals, Inc.
• 15. Denali Therapeutics Inc.
• 16. Eisai Co. Ltd.
• 17. Eli Lilly and Company
• 18. F. Hoffmann-La Roche AG
• 19. GlaxoSmithKline PLC
• 20. H. Lundbeck A/S
• 21. Intra-Cellular Therapies, Inc.
• 22. Ipsen S.A.
• 23. Johnson & Johnson Services, Inc.
• 24. Lupin Limited
• 25. MapLight Therapeutics, Inc.
• 26. Merck KGaA
• 27. Minerva Neurosciences, Inc.
• 28. Neuraxpharm
• 29. Novartis AG
• 30. Novo Nordisk A/S
• 31. Otsuka Holdings Co Ltd
• 32. Pfizer Inc.
• 33. Polpharma Biologics S.A.
• 34. Rapport Therapeutics, Inc.
• 35. Sage Therapeutics, Inc.
• 36. Sanofi S.A.
• 37. Sun Pharmaceutical Industries Limited
• 38. Supernus Pharmaceuticals, Inc.
• 39. Takeda Pharmaceutical Company Limited
• 40. TauRx Pharmaceuticals Ltd
• 41. Teva Pharmaceutical Industries Ltd.
• 42. UCB S.A.